LEXARIA BIOSCIENCE CORP. Earnings Per Share (Diluted)
LEXARIA BIOSCIENCE CORP. (LEXX) reported Earnings Per Share (Diluted) of -$0.08 per share for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for the quarter ending 2026-05-31 was -$0.08.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for the quarter ending 2026-02-28 was -$0.06.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for the quarter ending 2025-11-30 was -$0.07.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for the quarter ending 2025-08-31 was -$0.14.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for fiscal 2025 was -$0.66.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for fiscal 2024 was -$0.47.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for fiscal 2023 was -$1.01.
- LEXARIA BIOSCIENCE CORP. earnings per share, diluted for fiscal 2011 was -$0.04.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$0.08 10-Q · filed 2026-07-13 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.21 10-Q · filed 2026-07-13 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-07-13 |
| 2026-02-28 | -$0.06 10-Q · filed 2026-04-13 | -$0.13 10-Q · filed 2026-04-13 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-07-13 |
| 2025-11-30 | -$0.07 10-Q · filed 2026-01-13 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-07-13 |
| 2025-08-31 | -$0.14 derived: net income ÷ weighted average shares · filed 2025-11-28 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.66 10-K · filed 2025-11-28 |
| 2025-05-31 | -$0.21 10-Q · filed 2026-07-13 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.53 10-Q · filed 2026-07-13 | -$0.67 derived: net income ÷ weighted average shares · filed 2026-07-13 |
| 2025-02-28 | -$0.15 10-Q · filed 2026-04-13 | -$0.32 10-Q · filed 2026-04-13 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-07-13 |
| 2024-11-30 | -$0.16 10-Q · filed 2026-01-13 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-07-13 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-07-13 |
| 2024-08-31 | -$0.14 derived: net income ÷ weighted average shares · filed 2025-11-28 | -$0.27 derived: net income ÷ weighted average shares · filed 2025-11-28 | -$0.34 derived: net income ÷ weighted average shares · filed 2025-11-28 | -$0.47 10-K · filed 2025-11-28 |
| 2024-05-31 | -$0.13 10-Q · filed 2025-07-14 | -$0.20 derived: net income ÷ weighted average shares · filed 2025-07-14 | -$0.32 10-Q · filed 2025-07-14 | |
| 2024-02-29 | -$0.06 10-Q · filed 2025-04-14 | -$0.18 10-Q · filed 2025-04-14 | ||
| 2023-11-30 | -$0.13 10-Q · filed 2025-01-10 | |||
| 2023-08-31 | -$1.01 10-K · filed 2024-11-26 | |||
| 2012-07-31 | $0.00 10-Q · filed 2012-09-12 | -$0.02 10-Q · filed 2012-09-12 | ||
| 2012-04-30 | -$0.01 10-Q · filed 2012-06-07 | -$0.02 10-Q · filed 2012-06-07 | -$0.02 derived: net income ÷ weighted average shares · filed 2012-06-07 | -$0.04 derived: net income ÷ weighted average shares · filed 2012-09-12 |
| 2012-01-31 | -$0.01 10-Q · filed 2012-03-13 | -$0.01 derived: net income ÷ weighted average shares · filed 2012-03-13 | -$0.02 derived: net income ÷ weighted average shares · filed 2012-09-12 | -$0.04 derived: net income ÷ weighted average shares · filed 2012-09-12 |
| 2011-10-31 | $0.00 derived: net income ÷ weighted average shares · filed 2012-01-30 | -$0.02 derived: net income ÷ weighted average shares · filed 2012-09-12 | -$0.03 derived: net income ÷ weighted average shares · filed 2012-09-12 | -$0.04 10-K · filed 2012-01-30 |
| 2011-07-31 | -$0.02 10-Q · filed 2012-09-12 | -$0.03 derived: net income ÷ weighted average shares · filed 2012-09-12 | -$0.04 10-Q · filed 2012-09-12 | -$0.05 derived: net income ÷ weighted average shares · filed 2012-09-12 |
| 2011-04-30 | -$0.01 10-Q · filed 2012-06-07 | -$0.02 10-Q · filed 2012-06-07 | -$0.03 derived: net income ÷ weighted average shares · filed 2012-06-07 | -$0.03 derived: net income ÷ weighted average shares · filed 2012-06-07 |
| 2011-01-31 | -$0.01 10-Q · filed 2012-03-13 | -$0.02 derived: net income ÷ weighted average shares · filed 2012-03-13 | -$0.02 derived: net income ÷ weighted average shares · filed 2012-03-13 | |
| 2010-10-31 | -$0.01 derived: net income ÷ weighted average shares · filed 2012-01-30 | -$0.01 derived: net income ÷ weighted average shares · filed 2012-01-30 | -$0.04 10-K · filed 2012-01-30 | |
| 2010-07-31 | $0.00 10-Q · filed 2011-09-14 | -$0.04 10-Q · filed 2011-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |